GSK Pharma posts 21.3% PAT jump on land sale, revenue up 8.1% YoY

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
GSK Pharma posts 21.3% PAT jump on land sale, revenue up 8.1% YoY
Overview

GlaxoSmithKline Pharmaceuticals reported robust Q3 FY26 financial results, with standalone revenue rising 8.1% YoY to ₹1,02,259 lakhs and standalone Profit After Tax (PAT) surging 21.3% YoY to ₹27,718 lakhs. Consolidated PAT saw an even stronger jump of 28.6% YoY to ₹29,562 lakhs, significantly aided by an exceptional gain of ₹1,798 lakhs from a land sale. The nine-month period also showed growth, with consolidated PAT up 14.4% YoY. Implementation of new Labour Codes led to an incremental impact on employee benefits.

📉 The Financial Deep Dive

GlaxoSmithKline Pharmaceuticals (GSK Pharma) announced its financial results for the third quarter and nine months ended December 31, 2025, revealing a healthy year-on-year performance.

The Numbers:

For the third quarter (Q3 FY26):

  • Standalone revenue from operations increased by 8.1% year-on-year (YoY) to ₹1,02,259 lakhs.
  • Standalone Profit After Tax (PAT) saw a significant rise of 21.3% YoY, reaching ₹27,718 lakhs.
  • On a consolidated basis, revenue grew 9.7% YoY to ₹1,04,126 lakhs.
  • Consolidated PAT demonstrated substantial growth, up 28.6% YoY to ₹29,562 lakhs.
  • Basic and diluted EPS for standalone operations stood at ₹16.36, an increase from ₹13.49 in the prior year.
  • Consolidated EPS was ₹17.45, up from ₹13.57 YoY.

For the nine-month period ended December 31, 2025:

  • Standalone revenue was ₹2,80,105 lakhs, a 1.6% YoY increase.
  • Standalone PAT grew 11.8% YoY to ₹73,688 lakhs.
  • Consolidated revenue stood at ₹2,82,637 lakhs, up 1.9% YoY.
  • Consolidated PAT increased 14.4% YoY to ₹75,812 lakhs.

The Quality:

The robust growth in consolidated PAT for Q3 FY26 was primarily driven by exceptional gains amounting to ₹1,798 lakhs from the sale of a non-operational land site. While the underlying operational performance showed steady revenue growth, the significant PAT jump in the quarter is notably bolstered by this one-off event. The company also noted an incremental impact of ₹1,182 lakhs on employee benefits expense for both the quarter and nine-month period due to the implementation of new Labour Codes, indicating a cost factor to monitor.

The Grill:

The provided text does not contain information regarding management guidance, concall commentary, or specific details about analyst estimates versus reported figures. Therefore, an analysis of any management grill or beat/miss against analyst expectations cannot be performed based on this source.

Risks & Outlook:

Information regarding future outlook, specific growth drivers, or potential risks was not available in the provided text. Investors will need to await further commentary or future disclosures for insights into the company's forward-looking strategy and market positioning.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.